AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02643927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-week shortened MBSR
Description: This protocol was made up of 4 sessions of 120 mn administered by the same trained MBSR programme therapist to avoid variables associated to the therapist. The rationale behind the shortened version of MBSR was to keep the core content and practices of the program, in fewer sessions: raisin exercise (experiential concept of mindfulness); and main anchors of attention (breathing, body sensations, body movements).
Study NCT01377441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Patients will receive either 800mg IV ibuprofen or placebo pre-operatively. Post-operatively, patients will receive either 800mg IV ibuprofen or placebo 6 hours after the first dose.
Study NCT01377441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Saline solution
Description: Patients will receive placebo pre-operatively. Post-operatively, patients will receive placebo at least 6 hours after the initial dose.
Study NCT01145157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Signature Knee Guide
Description: Total Knee Arthroplasty performed using Signature Knee Guide
Study NCT01145157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Instrumentation
Description: Total Knee Arthroplasty performed using Conventional Instrumentation
Study NCT01145157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer Assisted Navigation
Description: Total Knee Arthroplasty performed using Computer Assisted Navigation
Study NCT03266276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSOPC pathway approach
Description: The intervention will use a standardized PSOPC pathway approach, prompted follow up with patients and documentation.~Additionally, clinicians will be prompted to document conversations about response to emotional or physical ESAS symptom scores, symptom management plan (self/education/monitoring/medication), illness understanding; and, if necessary, an offer of PSO/PC referral.
Study NCT02834962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single bundle ACL reconstruction
Description: anterior cruciate ligament reconstruction using single bundle technique
Study NCT02834962 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double bundle ACL reconstruction
Description: anterior cruciate ligament reconstruction using double bundle technique
Study NCT06697210 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: • Dental Floss (Vitis®, Dentaid, Barcelona, Spain).
Description: Dental Floss: A piece of dental floss approximately 40-50 cm in length was taken and placed between the index and middle fingers of each hand, leaving about 2-3 cm free in the middle. The floss was then inserted, embracing the mesial and distal surfaces, and moved up and down three times on each side
Study NCT06697210 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: • Superfloss (Oral B®, Procter & Gamble, USA)
Description: Superfloss: The stiffened end was used to introduce the thread and the spongy-floss into the interproximal area on both the mesial and distal parts, and a gentle back-and-forth motion was applied to remove bacterial plaque. The spongy-floss was then pulled through to the regular floss section and gently slid under the gumline, followed by an up-and-down motion. These movements were repeated three times on each side.
Study NCT06697210 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: • Oral irrigator (Waterpick®, Water Pik, Inc., CO., USA)
Description: Oral Irrigator: The finest tip was selected and placed in the mesiobuccal, distobuccal, mesiolingual, and distolingual interproximal spaces. The irrigator was activated at medium power (2/3), and the process was repeated three times on each side for five seconds.
Study NCT06697210 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: • Interproximal brushes (Interprox®, Vitis, Dentaid, Spain)
Description: Interproximal Brush Group: According to the interproximal space, the appropriate size was selected for each case. The brush was then placed horizontally in the interproximal space mesially and distally, and a back-and-forth movement was performed three times on each side.
Study NCT03709784 — intervention group
Intervention type: DRUG
Intervention: Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care
Description: This is an observational study of adult patients with SMA to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.
Study NCT03709784 — intervention group
Intervention type: OTHER
Intervention: One time survey
Description: One time survey
Study NCT00654940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin (Lyrica)
Description: Oral, 75mg or 150mg capsules, BID
Study NCT00654940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, matched capsules, BID
Study NCT02711072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 100 µ of intrathecal Morphine+ infiltration catheter with saline 5 ml/h
Study NCT02711072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 100 µ of intrathecal Morphine+ infiltration catheter with saline 5 ml/h
Study NCT02711072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: infiltration group
Description: spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 1ml of saline + infiltration catheter with 5 ml/h of Bupivacaïne 0,125%.
Study NCT02711072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infiltration group
Description: spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 1ml of saline + infiltration catheter with 5 ml/h of Bupivacaïne 0,125%.
Study NCT02471846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle with the exception of biopsy cohort A, where atezolizumab administration will start on Cycle 2 Day 1.
Study NCT02471846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0919
Description: Participants will receive GDC-0919 by mouth (PO) twice daily (BID), specifically every 12 hours. During the dose-escalation stage, the first cohort will receive GDC-0919 at a starting dose of 50 mg PO BID. Dosing will commence on Day -1 for Cycle 1 and follow subsequent 21-day (Days 1 to 21) dosing cycles. The dose will be modified based upon evaluation of DLTs, with single dose escalations not to exceed 2.5-fold of the previous dose. The proposed dosages for evaluation are 50, 100, 200, 400, 600, and 1000 mg PO BID. During the expansion stage, selected solid tumor types will be treated at the MTD or MAD as determined during the dose-escalation stage.
Study NCT02606669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal Replacement
Description: Using a Meal Replacement product, supplemented by protein powder and multivitamin
Study NCT01492855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopy
Description: Arthroscopy is offered for the patients who do not benefit from conservative treatment.
Study NCT01492855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-invasive treatment
Description: All patients will receive information and supervised exercises by a physiotherapist.
Study NCT00528190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral Itraconazole 5mg/kg/day or identical placebo for 24 weeks
Study NCT00528190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itraconazole
Description: Oral Itraconazole 5mg/kg/day or identical placebo for 24 weeks
Study NCT01870817 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Home jejunostomy feeding
Study NCT03312985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACAF surgery
Description: The main surgical procedures include discectomy of the involved levels, thinning of the anterior part of the involved vertebrae, intervertebral cages, anterior plate and screws installation, bilateral osteotomies of the vertebrae, and antedisplacement of the vertebrae-OPLL complex
Study NCT03312985 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ACCF surgery
Description: Removal of the vertebral body，exposed ossification of the posterior longitudinal ligament，and then removed
Study NCT04568707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample for serum (serology, biomarkers) and DNA
Study NCT03169374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Technology
Description: Patients in this arm will participate in virtual reality sessions planned for 5 minutes at a time, during which they are shown relaxing virtual environments.
Study NCT04063462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: pyrotinib, single agent, 400mg p.o once daily until disease progressed
Study NCT02752152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted counseling
Description: The counselor opens the computer-assisted information/educational interactive counseling program on the tablet computer and invites the participant to use the program.
Study NCT02752152 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-assisted counseling
Description: The counselor opens the computer-assisted information/educational interactive counseling program on the tablet computer and invites the participant to use the program.
Study NCT02752152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-demand counseling
Description: The counselor only invites the participants to ask questions about HIV and other STIs.
Study NCT02752152 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: On-demand counseling
Description: The counselor only invites the participants to ask questions about HIV and other STIs.
Study NCT04356378 — intervention group
Intervention type: OTHER
Intervention: Data record
Description: Data record
Study NCT02752152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard counseling
Description: The counselor gives face-to-face general information/education
Study NCT02752152 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard counseling
Description: The counselor gives face-to-face general information/education
Study NCT02752152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appointment + reminder
Description: Has an appointment and receive reminders for further testing
Study NCT02752152 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Appointment + reminder
Description: Has an appointment and receive reminders for further testing
Study NCT02752152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Only receive reminders for further testing
Study NCT02752152 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminder
Description: Only receive reminders for further testing
Study NCT02752152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No appointment and no reminder
Description: No appointment and no reminders for further testing
Study NCT02752152 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No appointment and no reminder
Description: No appointment and no reminders for further testing
Study NCT04537390 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sample collection
Description: Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development
Study NCT02858193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCMC-lys powder 1.35 g
Description: Powder for oral solution in sachets each containing 1.35 g of S-carboxymethyl-L-cysteine L-lysine monohydrate salt (SCMC-lys).~One sachet of the powder of the test formulation: (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) was dissolved in 100 mL of hot (not boiling) still mineral water. Additional 100 mL of still mineral water at room temperature were added and mixed. The solution was swallowed and the glass was rinsed with 40 mL of still mineral water that was also drunk by the subjects. The final administered volume was 240 mL. All subjects were in fasting conditions from the evening before (at least 10 h, overnight).The final administered volume was 240 mL for both the test and reference treatments.
Study NCT02858193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluifort® syrup
Description: Fluifort® 90 mg/mL syrup (15 mL corresponding to 1.35 g SCMC-lys)~Fifteen (15) mL of syrup (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) poured in a glass were drunk by the subjects. Afterward, the glass was rinsed twice with a volume of 100 mL and 125 mL of still mineral water and the rinses were drunk immediately by the subjects. The final administered volume was 240 mL for both the test and reference treatments.
Study NCT02836977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur-uracil
Description: Eligible patients will receive tegafur-uracil orally at a dose of 400mg/day (100mg/Cap., 2 capsules each time, twice a day) and folinic acid 30mg/day (15mg/Tab., 1 tablet each time, twice a day) for one year.
Study NCT02836977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tegafur-uracil
Description: Eligible patients will receive tegafur-uracil orally at a dose of 400mg/day (100mg/Cap., 2 capsules each time, twice a day) and folinic acid 30mg/day (15mg/Tab., 1 tablet each time, twice a day) for one year.
Study NCT01642186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study NCT01642186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole plus leuprolide
Study NCT01642186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of everolimus, letrozole and leuprolide
Study NCT04316455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Yoga Therapy
Description: Participants having an hour in-person weekly session with qualified yoga therapist for 6-weeks. At each session, the personalised yoga practices including straightening and relaxing posture of yoga, yoga breathing, Combinations of sound and imagery yoga practices were given and asked to continue practice at home during the week.
Study NCT02231580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN82451B
Description: BN82451B capsule
Study NCT02231580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT04297774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality treatment
Description: 18 virtual reality training through Pablo system (30 minutes a time, 2-3 times a week). Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. The controller was attached to lower extremity or trunk to control the game, such as elevator, hot air balloon, shooting cans, etc.
Study NCT04428970 — intervention group
Intervention type: PROCEDURE
Intervention: Invasive ICP monitoring
Description: Insertion of a parenchymal pressure measuring probe
Study NCT03459820 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL PET/CT
Description: 18F-DCFPyL Positron Emission Tomography/Computed Tomography Scan
Study NCT01474512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3
Description: Administered SC
Study NCT01474512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03917043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2449
Description: Capsule, multiple dose cohorts, oral administration every day (QD) of a 28-day cycle
Study NCT01118962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949). At the beginning of SP0962, the dose may be maintained, or increased or decreased by 100 mg /day, as deemed clinically appropriate to optimize tolerability and seizure reduction. Dose increases should be no faster than 100 mg/ day per week up to a maximum of 800 mg/ day. Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses for up to a 56-week Treatment Phase. The Treatment Phase was followed by a 5-week End-of-Study Phase, during which subjects had to be tapered off Lacosamide at a recommended decrease rate of 200 mg/ day per week.
Study NCT02749708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX5183
Description: IRX5183 will be administered orally daily on days 1-28 of each cycle for 2 cycles of induction. In the phase I part of the study, there will be 3 dose levels (dose level 1 \[DL1\] with 50 mg, DL2 with 75 mg, and DL3 with 100 mg), with 1 additional dose level to be only used if excessive toxicity noted at the DL1. There will be no intra-patient dose escalation. A phase II portion of the study was originally planned, but the study was terminated prior to phase II enrollment.
Study NCT04297774 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: 18 standard rehabilitation sessions (60 minutes a time, 2-3 times a week). The rehabilitative protocol focus on strengthening, endurance training, ambulation, and ADL training that included: (1) Hip flexor and knee extensor strengthening with resistance progressing used by weight bag or Thera-band. (2) Cycle ergometer riding with increase speed and resistance. (3) Gait pattern and speed correcting through treadmill and parallel bar. (4) Hand functional training and strategy teaching for feeding, dressing, and toileting.
Study NCT04297774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: 18 standard rehabilitation sessions (60 minutes a time, 2-3 times a week). The rehabilitative protocol focus on strengthening, endurance training, ambulation, and ADL training that included: (1) Hip flexor and knee extensor strengthening with resistance progressing used by weight bag or Thera-band. (2) Cycle ergometer riding with increase speed and resistance. (3) Gait pattern and speed correcting through treadmill and parallel bar. (4) Hand functional training and strategy teaching for feeding, dressing, and toileting.
Study NCT01089556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered orally
Study NCT01089556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Administered orally
Study NCT01089556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally, daily as a blind for duloxetine and/or pregabalin for 8 or 16 weeks
Study NCT01635894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Women in both the practice nurse and specialist nurse groups were given supervised pelvic floor exercise training. After the initial training they were given a daily exercise regimen and seen at monthly intervals for three months. The practice nurses had attended a study day on supervising Pelvic Floor Muscle Training(PFMT)followed by practice sessions with patients overseen by the nurse specialist.
Study NCT04497311 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thoraxic computed tomography
Description: Diagnostic lung CT.
Study NCT04297774 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: balance training
Description: 18 balance training sessions (30 minutes a time, 2-3 times a week) (1) Facilitated the balance reaction through weight shifting exercise with standing on even surface to uneven surface, such as tilting board.(2) Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. (3) Changed the standing requirement, such as single legged stance or lunge stance. (4) Increased perception complications through cognition or upper extremity task to improve dual task attention.
Study NCT02542280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial injury.
Description: Endometrial injury using a pipelle biopsy catheter on day (5, 6 or 7) of the stimulation cycle combined with the intrauterine insemination.
Study NCT02542280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intrauterine insemination
Description: Placement of washed sperm in the uterus using a catheter, around the time of ovulation.
Study NCT02542280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrauterine insemination
Description: Placement of washed sperm in the uterus using a catheter, around the time of ovulation.
Study NCT02542280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ovarian stimulation
Description: Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.
Study NCT02542280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ovarian stimulation
Description: Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.